| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2011: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Research Abstract |
The population of CKD patients in Japan is estimated as 13.3 million people. CKD is a risk factor of end-stage renal disease and cardiovascular disorders. Here, we examined the functional role of Vasohibin-1, a negative feedback regulator of angiogenesis, in CKD. Diabetic nephropathy, tubulointerstitial injuries induced by unilateral ureteral obstruction and acute kidney injury were exacerbated in the Vasofibin-1+/-- mice compared with the wild-type mice. Renal Vasohibin-1 expression was associated with crescentic lesions and interstitial inflammation in CKD patients. Elevated plasma/urinary levels of Vasohibin-1 predicted progressive renal functional deterioration in CKD patients. These results suggest the potential renoprotective effects of Vasohibin-1 and its potential as a novel biomarker in CKD.
|
